Protein Sequencing Market By Technology (Edman Degradation, Mass Spectrometry, Hybrid Techniques), By Application (Biopharmaceuticals, Academic & Research, Proteomics Research, Drug Discovery), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs)); Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Protein Sequencing Market was valued at USD 1.4 Billion in 2024-e and will surpass USD 3.4 Billion by 2030; growing at a CAGR of 16.2% during 2025 - 2030.

The protein sequencing market is witnessing significant growth due to increasing research in proteomics, biopharmaceutical development, and drug discovery. Advances in mass spectrometry and hybrid sequencing techniques have enhanced the accuracy and efficiency of protein analysis, driving adoption across pharmaceutical, biotechnology, and academic research institutions. With the rising demand for personalized medicine and biologics, protein sequencing technologies are playing a crucial role in understanding protein structures, modifications, and interactions.

Mass Spectrometry Segment Is Largest Due to High Precision and Versatility

Mass spectrometry is the largest segment in the protein sequencing market, owing to its high sensitivity, accuracy, and ability to analyze complex protein structures. This technique is widely used in proteomics research, biomarker discovery, and biopharmaceutical development. Mass spectrometry provides detailed insights into protein modifications, post-translational changes, and molecular interactions, making it an essential tool in drug development and clinical diagnostics. Continuous advancements in mass spectrometry instruments, coupled with the integration of artificial intelligence for data analysis, are further strengthening the dominance of this segment.

Drug Discovery Segment Is Fastest Growing Due to Rising Demand for Targeted Therapies

The drug discovery application segment is experiencing the fastest growth, fueled by the increasing need for novel therapeutics, biologics, and personalized medicine. Protein sequencing plays a critical role in identifying drug targets, characterizing protein-based therapeutics, and optimizing biologic drug formulations. Pharmaceutical companies are leveraging sequencing technologies to improve drug efficacy, minimize side effects, and accelerate clinical trials. The growing adoption of monoclonal antibodies and peptide-based drugs has further amplified the demand for precise protein sequencing solutions.

Pharmaceutical & Biotechnology Companies Segment Is Largest Due to High Adoption in Biologics Development

Pharmaceutical and biotechnology companies constitute the largest end-user segment, driven by the increasing focus on biologics, biosimilars, and targeted therapies. Protein sequencing is crucial for ensuring the quality, stability, and efficacy of biologic drugs, making it an integral part of biopharmaceutical manufacturing. Companies are investing heavily in proteomics research and bioanalytical tools to enhance their drug discovery pipelines. Additionally, regulatory agencies are emphasizing stringent quality control measures for biologics, further boosting the demand for advanced protein sequencing technologies.

North America Is Largest Due to Strong Research Infrastructure and Biotechnology Presence

North America leads the protein sequencing market due to its well-established biotechnology and pharmaceutical industries, strong government funding for proteomics research, and presence of major market players. The region benefits from advanced research institutions, a growing number of clinical trials, and widespread adoption of precision medicine. Furthermore, increasing collaborations between biotech firms and academic institutions for protein analysis and drug development are propelling market growth. The rising demand for high-throughput sequencing technologies and AI-driven bioinformatics solutions further strengthens North America’s dominant position.

Leading Companies and Competitive Landscape

The protein sequencing market is highly competitive, with key players such as Thermo Fisher Scientific, Agilent Technologies, Shimadzu Corporation, Waters Corporation, and Bruker Corporation driving innovation. Companies are focusing on expanding their mass spectrometry capabilities, integrating AI-based data analytics, and developing hybrid sequencing technologies to enhance accuracy and throughput. Strategic partnerships, mergers, and acquisitions are common strategies employed to strengthen market presence and expand product offerings. With the increasing focus on proteomics and biologics, the protein sequencing market is expected to continue its growth trajectory, particularly in drug discovery and personalized medicine applications.

List of Leading Companies:

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bruker Corporation
• Shimadzu Corporation
• Waters Corporation
• Bioinformatics Solutions Inc.
• Proteome Factory AG
• Charles River Laboratories International, Inc.
• Creative Proteomics
• Rockland Immunochemicals, Inc.
• Rapid Novor Inc.
• Selvita S.A.
• Biognosys AG
• JPT Peptide Technologies GmbH
• GenScript Biotech Corporation

Recent Developments:

• Thermo Fisher Scientific Inc. launched an advanced mass spectrometry system for high-resolution protein sequencing in February 2025.
• Agilent Technologies, Inc. expanded its proteomics portfolio with a new peptide sequencing workflow in January 2025.
• Bruker Corporation introduced a next-generation MALDI-TOF mass spectrometer for proteomics research in December 2024.
• Waters Corporation partnered with a biotech firm to enhance protein structure analysis capabilities in November 2024.
• Bioinformatics Solutions Inc. announced the development of AI-driven protein sequencing software for drug discovery applications in October 2024.

Report Scope: